▶주메뉴 바로가기

▶본문 바로가기

THE INVESTOR
December 12, 2018
Big Reunion

Bio & Medicine

Boryung Vigencell to enter phase 2 studies on T-cell immunotherapy

  • PUBLISHED :December 29, 2017 - 15:14
  • UPDATED :December 29, 2017 - 15:14
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print

[THE INVESTOR] Boryung Vigencell, an affiliate of Korean drug maker Boryung Pharmaceutical, said on Dec. 28 that the country’s regulator has approved its Investigational New Drug application to initiate phase 2 clinical trials of its T-cell immunotherapy.

The company was able to create tumor-specific cytotoxic T-cells -- which play a vital role in the immune response against cancer -- by cultivating T-cells derived from blood. With the approval, Boryung Vigencell will now conduct studies of the drug candidate on patients with lymphoma caused by the Epstein-Barr virus. 




Boryung Vigencell hopes to gain conditional approval from phase 2 studies to be given market access prior to phase 3 clinical trials. This would help the company commercialize the investigational drug as early as 2021 after completing the mid-stage studies.

Boryung Pharmaceutical acquired Vigencell, which was a biotech venture under the Catholic University of Korea, in 2016.

By Park Han-na (hnpark@heraldcorp.com)

  • facebook
  • twitter
  • sms
  • print

EDITOR'S PICKS